All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The mechanisms of maternal psychosocial stress affecting the fetus during pregnancy are assumed to be regulated by placental transfer of hormones, through changes in the expression of placental receptors and enzymes (for reviews, see \[[@pone.0233979.ref001],[@pone.0233979.ref002]\]).

The placenta consists of different cell layers in the human placenta and the layer most representative of the placental transport and metabolism is the syncytiotrophoblast. This cell layer expresses the enzyme 11β-Hydroxysteroid dehydrogenase (11β-HSD2), which transforms 80--90% of the maternal cortisol to cortisone before translocating on to the umbilical and fetal blood \[[@pone.0233979.ref003],[@pone.0233979.ref004]\]. The activity of 11β-HSD2 has been linked to the effect of maternal psychosocial stress on the offspring, as it protects the fetus from the high cortisol plasma levels of the pregnant woman (for a review see \[[@pone.0233979.ref005]\]).

Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter that also plays a role during early development of the human fetus, where it acts as a growth factor, regulating the development of fetal neural systems. Serotonin is important for the development of the hypothalamic-pituitary-adrenal (HPA) axis, and acts as a mediator between early life experience and subsequent behaviour \[[@pone.0233979.ref006]\]. Transplacental transport of serotonin occurs via the 5-HT transporter (SERT) and via placental metabolism of tryptophan \[[@pone.0233979.ref007],[@pone.0233979.ref008]\]. In the placenta serotonin is metabolized into 5- hydroxyindoleacetic acid (5-HIAA) by monoamine oxidase A (MAO A) \[[@pone.0233979.ref009]\].

Tryptophan is the essential amino acid utilized for the synthesis of serotonin and the hormone melatonin, although degradation of tryptophan occurs mostly (95%) along the kynurenine pathway with one of the end products being nicotinamide adenine dinucleotide (NAD^+^). The first step in the kynurenine pathway occurs via three enzymes, indoleamine 2,3-dioxygenase-1 and -2 (IDO1 and IDO2), and tryptophan 2,3-dioxygenase (TDO) which can be induced by cortisol. Tryptophan hydroxylases (TPH1 and TPH2) is part of the pathway to synthesize serotonin. It is suggested that both IDO1, IDO2, and TDO and TPH are located in the human placenta, where they play a part in utero-placental immune system regulation, feto-maternal tolerance, antioxidant capacity and vasorelaxation \[[@pone.0233979.ref010]\].

In an earlier study from our group, the effect of prenatal maternal psychosocial stress on the adjusted fetal cortisol exposure (AFCE) was described in a normal pregnant population \[[@pone.0233979.ref011]\]. The AFCE was calculated to represent the relative amount of cortisone produced by the placenta measured in fetal blood in relation to how much cortisol crosses the placenta un-metabolized from maternal blood, corrected for the interindividual differences of these hormone levels in the population--i.e. the placental exposure. The AFCE provide a measure of the activity of the enzyme 11β-HSD2 and thus an increase in the AFCE represents a relative increase in fetal cortisol exposure.

Direct characterization of transport and metabolism of stress-related hormones in the human placenta is of significant importance to understand potential pathophysiological mechanisms. Therefore, using placentas from a previously studied population \[[@pone.0233979.ref011]\] and *ex vivo* placental perfusion, the aims of the present work was in human term placentas with known prenatal stress levels to describe the transport and metabolism of i) cortisol, ii) cortisone, iii) tryptophan and iv) serotonin. Finally, addition of inhibitors of placental enzymes 11β-HSD2, SERT and THP aimed to v) give insight into the supposed effect of maternal stress on the placenta and thus fetal exposure.

Materials and methods {#sec006}
=====================

The current study is a part of the '*Maternal Stress and Placental Function'* project, conducted in Copenhagen, Denmark, described in detail in a previous publication \[[@pone.0233979.ref011]\]. Briefly, participants were pregnant women giving birth at Copenhagen University Hospital. The project was approved by the Regional Scientific Ethical Committee of Copenhagen (H-15006254) and the Danish Data Protection Agency (2015-41-4208). All women were informed about the aim of the study, gave written informed consent and were instructed to answer four written questionnaires in order to measure: 1: relevant personal factors such as socioeconomic status, use of medication, smoking, and alcohol consumption during and before pregnancy, 2: pregnancy-related anxiety, 3: personality, and 4: prevalence of prenatal depression, anxiety and stress. Twenty-two placentas were set up in placental perfusion. Of these, 2 perfusions had a leak of medium from fetal circulation and were unsuccessful,5 perfusions showed a leak of medium from the fetal circulation after 4 hours perfusion and were thus unsuccessful after this time-point, and 15 were successful 6-hour perfusions.

Psychometric measures {#sec007}
---------------------

Maternal *state* stress was defined as the degree of depression, anxiety and stress (DASS) experienced during the pregnancy, pregnancy- and birth-related thoughts and anxiety (PRA), and the experience of major life events during pregnancy. Maternal *trait* stress was represented by the maternal personality traits: neuroticism and conscientiousness, using the Danish version of the NEO-FFI inventory. These measures were assessed as described in a previous paper \[[@pone.0233979.ref011]\].

Placental perfusion {#sec008}
-------------------

The basic placental perfusion method was performed in Copenhagen, and is previously described and validated \[[@pone.0233979.ref012],[@pone.0233979.ref013]\]. In this study, the perfusions were performed on placentas delivered by women participating in the '*Maternal Stress and Placental Function study*', also donating blood and umbilical cord blood. To set up the perfusion, the placenta was infused with Krebs ringer buffer supplemented with heparin directly after birth, and cord blood sampling at the Copenhagen University Hospital. Hereafter, it was transported to the perfusion laboratory were a suitable artery-vein pair was cannulated to perfuse a single cotyledon. The cotyledon was removed from the surrounding tissue and placed in the perfusion chamber maternal side up. The perfusion chamber with the placental lobule was then moved to a heated flowbench (37°C) where fetal artery cannula was attached to a peristaltic pump. If the flow through the fetal vessels indicated that they were intact, the maternal side was bluntly cannulated with three metal cannula attached to a tube connected to a peristaltic pump, perfusing the maternal side of the cotyledon with 300 ml RPMI 1640 cell culture medium to wash out maternal residual blood. After this washing step, the fetal and maternal systems were closed to recirculate perfusion medium (100 ml RPMI 1640 cell culture medium with physiological levels of human serum albumin (HSA)) in a 1 hour pre-perfusion, the maternal outflow was drained by gravity ([Fig 1](#pone.0233979.g001){ref-type="fig"}).

![The placental perfusion system set-up.\
The full picture shows the perfusion set-up in the heated flowbench. At the left is the fetal reservoir and tubes with bubble-trap recirculating perfusion medium. In the middle is the placental lobule in the perfusion chamber. At the right is the maternal reservoir and tubes, recirculating medium, with three maternal cannula and gravitational collection of the outflow. The small cutout picture at the right is a closer view of the lobule and the three maternal cannula, with the light colored cotyledon caused by absence of blood.](pone.0233979.g001){#pone.0233979.g001}

Following the pre-perfusion was the six hour perfusion with 100 ml fresh perfusion medium in the maternal circulation added test substances (All from Sigma-Aldrich, Broendby, Denmark): physiological levels of cortisone (0.2 μg/ml), cortisol (0.2 μg/ml), tryptophan (13 μg/ml) and serotonin (0.3 μg/ml) (n = 22). Five of these perfusions were added carbenoxolone (50 μg/ml), an inhibitor of 11β-HSD2, four were added fluoxetine (SERT inhibitor) (0.5μg/ml), and five were added PCPA (binds irreversibly to tryptophan hydroxylase) (300μg/ml) (All from Sigma-Aldrich, Broendby, Denmark). The test substances and the control substance antipyrine were added to the maternal reservoir at start perfusion (time 0). Samples were taken out from maternal and fetal reservoir at time 0, 2, 30 minutes and thereafter at 30 minutes intervals until the end of perfusion. Oxygen level, glucose levels and pH in maternal and fetal circulation and fetal outflow, were measured during the perfusion using an ABLflex 90 blood gas analyzer (Radiometer, Denmark), and where regulated to stay in physiological levels. The volume of the fetal reservoir was observed after each sample, and at the end of perfusion, fetal and maternal volumes were measured. Success criteria were fetal system volume loss of less than 3 ml/h and antipyrine feto-maternal ratio (FM-ratio) above 0.75 after 150 minutes.

Quantification of antipyrine {#sec009}
----------------------------

Supernatant (200 μL) was mixed with Acetonitrile (200μL, VWR, Fontenay-Sous-Bois, France) to precipitate protein, containing 10 μg/mL phenacetin (*p*-acetopenetidide 97%, Acros organics, Geel, Belgium) as internal standard. Antipyrine (98%, Aldrich-Chemie, Steinheim, Germany) and phenacetin was analyzed using a reverse phase LaChrom HPLC system equipped with a L-7100 pump, an L7200 autosampler, an D-7000 interface, a L-7300 column oven and a L-7400 UV detector (Merck, Hitachi). The stationary phase was a C18 column (NUCLEOSIL C-18, ODS, 20 mm × 4.6 mm, 5 μm particles) with a Security Guard precolumn (Phenomexes C-18, ODS, 4 mm *L* × 3.0 mm i.d.). Mobil phase was a degassed methanol (HPLC grade, Applichem, Biochemia, Damstadt, Germany) and water (45/55, v/v) solution adjusted to a flow rate of 1 mL/min. Injection volume was 25 μL, oven temperature 31°C, and detection absorbance 254 nm.

Quantification of cortisol and cortisone {#sec010}
----------------------------------------

The quantification method of cortisol and cortisone is described in detail elsewhere \[[@pone.0233979.ref011]\].

In brief: Sample analysis was performed using a Waters (Milford, MA, USA) Acquity UPLC system with a Kinetex® 2.6 μm EVO C18 column (100Å 100x2.1 mm; Phenomenex, Torrance, CA, USA). Column temperature was 50°C, flow rate was 500 μl/min, and injection volume was 5 μl. The total analysis time was 9 minutes per sample. The mobile phase was a gradient of a mixture of an aqueous mobile phase 0.1% NH~4~OH (v/v) in water (mobile phase A) and an organic phase containing 0.1% NH~4~OH (v/v) in MeOH (mobile phase B).

Quantification of tryptophan, serotonin and -metabolites {#sec011}
--------------------------------------------------------

Tryptophan, serotonin (5-HT) and the 5-HT metabolite 5-hydroxyindoleaetic acid (5-HIAA) were examined by use of UHPLC. Perfusate samples were mixed at a ratio of 1:10 with 0.2 M HClO~4~ and centrifuged at 14000 g for 10 min. The supernatant was transferred to Costar cellulose acetate filter tubes (0.22 μm; Corning Inc) and centrifuged at 4°C for 10 min at 14 000 x g. For the measurement of 5-HT and 5-HIAA the filtrate was injected directly into the high-pressure liquid chromatography system. For the measurement of Trp 0.2 M perchloric acid was used to dilute the samples a further 50x. Chromatographic conditions were as follows: equipment consisted of Dionex Thermo Scientific Ultimate 3000 model isocratic pump and autosampler equipped with a Phenomenex Kinetix C18 2.6 μm, 150 x 4.6mm particle column. Detection of 5-HT and 5-HIAA was carried out using a Thermo Scientific Dionex model 6011RS ultra Coulometric Analytical cell (E1: -150 mV: E2: +250 mV vs Pd reference). The column was maintained at 27°C while eluting the analytes with a MDTM mobile phase (Thermo Scientific Dionex Test Phase, 70--3829) at a flow rate of 1.0 mL/min. Tryptophan measurements were performed using the same conditions as for 5-HT and 5-HIAA but with cell potentials at E1: +250 mV: E2: +550 mV vs Pd reference.

Statistical analysis {#sec012}
--------------------

All statistical testing was performed in IBM SPSS Statistics 24. Correlations were tested using bivariate correlations test. Descriptive results are presented as mean and range. Due to small group sizes, effects of inhibitors on the transplacental transfer of cortisol, cortisone, tryptophan and serotonin is not tested statistically, and figures are depicted as mean without standard deviation. A p-value less than 0.05 is interpreted as statistically significant.

Results {#sec013}
=======

Out of all placentas donated and handled, 31% resulted in a successful 6-hour perfusion (see [S1 Table](#pone.0233979.s001){ref-type="supplementary-material"}).

Perfusion variables and substances added are shown in [Table 1](#pone.0233979.t001){ref-type="table"}. All perfusions are simultaneously added cortisol, cortisone, tryptophan and serotonin. Out of the performed 22 perfusions, 7 fetal circulations became leaky (volume loss on fetal side \> 3ml/hour) after 1--5.5 hours perfusion. Only samples from non-leaky parts of perfusions (volume loss in fetal system \< 3ml/hour) until and over 4 hours are part of the graphs presented. All perfusion data are interpreted according to the mean of 3--8 repeated perfusions presented as percentage (%) of added substances in each individual perfusion, for raw data with concentrations (in nM) see [S1 Data](#pone.0233979.s005){ref-type="supplementary-material"}

10.1371/journal.pone.0233979.t001

###### Details of each perfusion performed in the maternal stress and placental function project.

All perfusions (n = 22) are added cortisol (0.2 μg/ml), cortisone (0.2 μg/ml), tryptophan (13 μg/ml) and serotonin (0.3 μg/ml) on maternal side at time 0.

![](pone.0233979.t001){#pone.0233979.t001g}

  ID   Antagonist      Time birth to lab (min)   Cotyledon weight (g)   Fetal flow (ml/2min)   Mean O~2~ Maternal   Mean O~2~ Fetal   Fetal volume loss 6h (ml/h)   Perfusion ok (h)
  ---- --------------- ------------------------- ---------------------- ---------------------- -------------------- ----------------- ----------------------------- ------------------
  1    none            33                        20                     5.9                    15.2                 13.1              2.0                           6
  2    none            40                        29                     6.0                    \-                   \-                1.4                           6
  3    none            33                        10                     5.8                    \-                   \-                0.1                           6
  4    none            36                        20                     5.8                    17.2                 9.4               0.9                           6
  5    none            44                        13                     6.2                    11.2                 7.0               1.4                           6
  6    none            57                        20                     6.6                    14.6                 5.8               2.6                           6
  7    none            50                        \-                     5.6                    13.6                 10.2              0.4                           6
  8    none            62                        11                     5.4                    16.5                 12.7              0.6                           6
  9    carbenoxolone   33                        13                     6.0                    15.0                 9.4               1.1                           6
  10   carbenoxolone   39                        18                     6.7                    \-                   \-                10.1                          1
  11   carbenoxolone   40                        24                     6.1                    12.3                 5.4               2.7                           6
  12   carbenoxolone   74                        11                     6.1                    12.6                 6.0               0.4                           6
  13   carbenoxolone   40                        7                      6.0                    16.0                 6.4               8.6                           3.5
  14   fluoxetine      43                        16                     6.3                    16.5                 9.2               1.9                           6
  15   fluoxetine      32                        20                     6.0                    9.9                  4.1               5.0                           5.5
  16   fluoxetine      42                        16                     6.4                    16.9                 16.4              6.4                           5
  17   fluoxetine      31                        22                     6.1                    15.5                 7.0               4.4                           5.5
  18   PCPA            44                        17                     6.3                    15.6                 11.0              1.0                           6
  19   PCPA            50                        7                      5.9                    14.7                 2.26              9.6                           4
  20   PCPA            38                        22                     5.7                    11.1                 4.1               0.7                           6
  21   PCPA            42                        30                     5.7                    12.7                 2.5               8.4                           4
  22   PCPA            71                        14                     5.7                    17.3                 9.5               1.3                           6

The majority of the donating mothers were non-smokers who did not drink alcohol during the pregnancy. The age span was 24 years with a mean age of 35, and a mean body mass index (BMI) before pregnancy of 23. Almost half of the women had a chronic disease, 6 had gestational complications and 7 took medication during pregnancy (analgesics, antibiotics, cobalamin, asthma medication and insulin) (see [S2 Table](#pone.0233979.s002){ref-type="supplementary-material"}).

Cortisol and cortisone {#sec014}
----------------------

The concentration of cortisol in the maternal circulation decreased rapidly to below 10% after 60 minutes perfusion with a plateau after approximately two hours perfusion. In the fetal circulation, the concentration of cortisol increased rapidly in the first thirty minutes and reached a plateau at equilibrium with the maternal side concentration after two hours perfusion. The addition of carbenoxolone caused a somewhat slower maternal decrease and higher fetal increase in cortisol concentration and a plateau around 4% of initial maternal concentration, compared to a plateau around 2% for the perfusions without carbenoxolone ([Fig 2](#pone.0233979.g002){ref-type="fig"} left graph).

![Placental perfusion with cortisol and cortisone with and without carbenoxolone.\
The graphs show maternal (red) and fetal (blue) mean concentration of cortisol (left graph) and cortisone (right graph), without (green circle, n = 8) and with (black triangle, n = 3) the addition of carbenoxolone. The concentration is presented as percentage (%) of the concentration found in the maternal sample at time 0 minutes perfusion.](pone.0233979.g002){#pone.0233979.g002}

The perfusions with cortisone showed an increase in cortisone concentration in the maternal circulation followed by a slow decrease. There was an immediate rapid increase of cortisone in the fetal circulation that surpassed the concentration on maternal side within a few hours perfusion. When adding carbenoxolone the initial increase of cortisone in the maternal circulation failed to appear but the slow decrease that followed was similar. The initial increase in the cortisone concentration in fetal circulation was similar to perfusions without carbenoxolone, but with a plateau after two hours ([Fig 2](#pone.0233979.g002){ref-type="fig"} right graph).

Tryptophan and serotonin {#sec015}
------------------------

Tryptophan showed a steady increase in the fetal side throughout the 6 hours perfusion without reaching an equilibrium. At end of perfusion the concentration of tryptophan in the fetal system had reached approximately 70% of the maternal start tryptophan concentration. The tryptophan concentration in the maternal system fell to a plateau around 75% of initial concentration after 3 hours perfusion. When adding fluoxetine or PCPA there was a slight increase in the tryptophan concentration on the maternal side at start perfusion before falling to 75% of initial concentration, and with fluoxetine in the maternal system the tryptophan concentration seemed to increase after 2 hours perfusion reaching 90% of initial concentration after 6 hours perfusion ([Fig 3](#pone.0233979.g003){ref-type="fig"} left graph).

![Placental perfusion with tryptophan and serotonin with and without fluoxetine and PCPA.\
The graphs shows maternal (red) and fetal (blue) mean concentration of tryptophan (left graph) and serotonin (right graph), without (green circle, n = 8) and with the addition of fluoxetine (black square, n = 4) and PCPA (red triangle, n = 5). The concentration is presented as percentage (%) of the concentration found in the maternal sample at time 0 minutes perfusion. The concentration of serotonin in all fetal system samples is subtracted the concentration of serotonin in the fetal system at time 0 minutes perfusion.](pone.0233979.g003){#pone.0233979.g003}

Serotonin concentration declined rapidly in the maternal system and reached a plateau after 2--4 hours perfusion at 0.2% of initial serotonin concentration. In the fetal system a small flat peak was seen at 1 hour perfusion of 0.2% of initial maternal concentration, where after the concentration of serotonin in the fetal system fluctuated close to 0 for the remainder of the 6 hours perfusion. The addition of fluoxetine slowed the rapid decline in the maternal concentration of serotonin, which reached 6% of initial concentration in maternal system after 2 hours perfusion and further declined to 0.8% at 6 hours perfusion. In the fetal system the initial peak of fluoxetine at 1 hour perfusion was markedly increased to 1% of initial maternal concentration when adding fluoxetine ([Fig 3](#pone.0233979.g003){ref-type="fig"} right graph).

The concentration of 5HIAA produced by the placenta reached a plateau after 120 minutes perfusion between 2.5--5% of the added amount of serotonin in maternal perfusate, and around 1% in the fetal perfusate with a second increase up to around 2% after 240 minutes perfusion. The addition of PCPA seems to slighty lower the production of 5HIAA ([Fig 4](#pone.0233979.g004){ref-type="fig"}).

![Placental perfusion with 5-HIAA.\
The graphs shows maternal (red) and fetal (blue) mean 5-HIAA concentration presented as percentage (%) of the 5-HT concentration in the maternal sample at time 0 minutes perfusion, without (green circle, n = 6) and with the addition of fluoxetine (black square, n = 4) and PCPA (red triangle, n = 5). The concentration of 5-HIAA in nM at each time point is subtracted the 0/before-sample concentration in nM in each perfusion on maternal and fetal side respectively.](pone.0233979.g004){#pone.0233979.g004}

Maternal stress related data (life events, Depression, Anxiety and Stress, PRA, neuroticism, conscientiousness and AFCE) and selected fetal exposure variables from the placental perfusions (cortisol concentration in fetal system at 30 minutes, difference in fetal system cortisol concentration between 30 and 300 minutes, serotonin concentration in fetal system at 60 minutes perfusion, difference in fetal system serotonin from 60 to 300 minutes, and placental production of 5-HIAA) are presented in [S3 Table](#pone.0233979.s003){ref-type="supplementary-material"}. The majority of the participating mothers had a normal depression, anxiety and stress levels, and normal or mild pregnancy related anxiety. Correlations test of stress parameters and data representing placental transport of cortisol and serotonin only showed correlations between related stress parameters, and correlations between related placental transport variables ([S4 Table](#pone.0233979.s004){ref-type="supplementary-material"}).

Discussion {#sec016}
==========

Placental transport and metabolism {#sec017}
----------------------------------

The endogenous concentration of cortisol, cortisone, tryptophan and serotonin fluctuate differently, and physiological levels in plasma during pregnancy is admittedly not representative for these fluctuations, especially at a cellular level. We aimed to use physiological start concentrations of the four hormones, except for that cortisone was added at the same concentration as cortisol (10x physiological), and medical indicated doses for carbonoxolone, fluoxetine and PCPA.

The performed placental perfusions showed a rapid metabolism of cortisol into cortisone with 2% cortisol left in both fetal and maternal circulations. The rapid metabolism of cortisol into cortisone by placental 11β-HSD2 confirms previous placental perfusion studies of cortisol \[[@pone.0233979.ref014]\]. The addition of the enzyme inhibitor carbenoxolone affected this metabolism in our study, as the initial increase of cortisone in maternal circulation was not found in the perfusions with added carbenoxolone, and the concentrations in both fetal and maternal circulations were generally higher for cortisol and lower for cortisone. We still saw some metabolism of cortisol into cortisone when adding carbenoxolone probably caused by the relatively low concentration of inhibitor added.

In another study it is shown that the passive transport of cortisol in the placenta from maternal to fetal side is low at low concentrations (20--200 nM), but is increased at high (800 nM) concentrations, were 1/8 of the concentration (100 nM) is transferred to fetal side. When carbenoxolone is added the transfer is increased to 200 nM on fetal side \[[@pone.0233979.ref015]\]. Those data are the result of an open circuit placental perfusion, with a constant concentration of cortisol on maternal side, as opposed to the closed loop study in this paper were cortisol is metabolized and eliminated from the system on both fetal and maternal side. In the open-loop study it is also concluded that the metabolism of cortisone into cortisol is negligible (3--4 nM in the high concentration), although also inhibited by carbenoxolone. The placenta favoring the metabolism of cortisol into cortisone was confirmed by another closed loop study, which also demonstrated increased output of corticotropin-releasing hormone (CRH) into the fetal vein when perfusing the human placenta with cortisol \[[@pone.0233979.ref016]\].

Our perfusion studies of tryptophan and serotonin showed rapid decline and low levels at the end of the 6 hours perfusion of serotonin on both maternal and fetal side. The surplus concentration of tryptophan at end perfusion is probably endogenous tryptophan washed out of the placental tissue during the 6 hours perfusion. When adding fluoxetine to the perfusions there was an initial peak of serotonin concentration in the fetal system. The fetal supply of serotonin has been suggested to originate from tryptophan from the maternal blood metabolized into serotonin in the placenta by THP-1 \[[@pone.0233979.ref007]\], or more recently, to come from a pathway of serotonin from maternal blood through the placenta via SERT, gap junctions, organic cation transporters and P-glycoprotein \[[@pone.0233979.ref017]\]. In both these pathways the enzyme MAOA rapidly oxidizes and eliminates excess serotonin in the placenta. We showed increased initial concentration of both tryptophan and relative serotonin concentration in the maternal system when adding fluoxetine, so both these pathways could supply the initial peak of serotonin in the fetal circulation. Alternatively the increased serotonin could be a result of fluoxetine inhibiting uptake in platelets via SERT \[[@pone.0233979.ref018],[@pone.0233979.ref019]\], although the fetal and maternal blood residues are mostly washed out from the placental lobule during the initial washing phase and pre-perfusion. The 5-HIAA levels we saw in the 6 hours placenta perfusion experiment only reached 7% of added serotonin, combined maternal and fetal system, which is less than expected.

When studying the placental transport of hormones there are possible interactions to take into account, in this study especially the feedback mechanism of cortisol on the metabolism of tryptophan into serotonin. Upregulation of TDO by cortisol causes increased metabolism of tryptophan into kynerunine and less into serotonin. The addition of cortisol in the perfusion studies of tryptophan metabolism is therefore physiologically relevant and a strength of this study.

The feed-forward mechanism of serotonin on cortisol cannot be studied on the isolated placenta, as this involves the maternal HPA axis \[[@pone.0233979.ref006]\]. However, it is interesting to consider the delayed decrease in maternal serotonin concentration due to fluoxetine, and the possibility of this affecting the maternal HPA axis.

Population and method {#sec018}
---------------------

Our study population is a relatively unselected section of the population, and therefore represents pregnant women subjected to everyday stressors and pregnancy anxiety. We were not able to demonstrate a possible influence of self-reported maternal stress levels on placental tissue in this study, due to very similar normal stress levels in the participating women.

The chosen concentrations of hormones and enzyme/receptor inhibitors were based on the physiological levels, the limit of quantification of the substance quantification method, and the water-solubility of the substances.

The human *ex vivo* placenta perfusion technique is a superior alternative to animal studies. In the field of hormones and stressors during pregnancy the complexity of the human experience is difficult to replicate in an animal model, as the effect of pregnancy on the maternal physiology and mental state is unique. Moreover the developmental stages of the fetus are very species specific, but most importantly there are huge species differences in the placenta, which is the most diverse mammalian organ \[[@pone.0233979.ref020]\].

Conclusion {#sec019}
==========

Perfusions were performed on twenty-two placentas studying the effect of maternal stress levels and relevant enzymes on the placental transfer and metabolism on four chosen hormones: cortisol, cortisone, tryptophan and serotonin. The addition of carbenoxolone inhibitis the metabolism of cortisol in the placenta, and this increased the fetal levels of cortisol in our experiments as expected. Unexpectedly we saw a peak in fetal levels of serotonin an hour after beginning perfusion, in placental perfusions of serotonin with added fluoxetine that inhibits the serotonin transporter. This was observed together with a delayed decrease in serotonin concentration on maternal side which suggests that the increased fetal levels of serotonin is caused by increased serotonin concentration on the maternal side of the placenta, perhaps enabling other transplacental serotonin transport routes than through the SERT. The effect of maternal stress on placental transporters and enzymes represented in this study by adding inhibitors, can thus affect the fetal exposure to maternal cortisol and serotonin levels. The more direct interpretation is increased transient exposure to both cortisol and serotonin when treating pregnant women with enzyme inhibitors. The increased fetal exposure to serotonin when inhibiting the SERT is an interesting finding, especially as regards to pregnant women needing treatment with SSRIs due to major depressive disorder and PTSD. No effect on placental kinetics was seen on maternal stress levels during the pregnancy, which is probably due to small group size in this study and the low to normal stress levels in the majority of most participating mothers.

Supporting information {#sec020}
======================

###### Successful perfusions in the maternal stress and placental function project according to success criteria.

The three success criteria are defined at different stages of the placental perfusion process: Criteria 1 is a successful cannulation, criteria 2 is a successful preperfusion, and criteria 3 is a successful 6 hour perfusion with added test-substances.

(DOCX)

###### 

Click here for additional data file.

###### Descriptive data.

Lifestyle, self-reported health and birth-related outcomes from the women donating the perfused placentas (n = 22).

(DOCX)

###### 

Click here for additional data file.

###### Stress related questionnaire data from the women donating the perfused placentas, and selected fetal perfusion medium cortisol and serotonin variables.

State stress represented by DASS, PRA, life events and adjusted fetal cortisol exposure (AFCE), trait stress represented by NEO-FFI categories neuroticism and conscientiousness. Cortisol concentration in the fetal system after 30 minutes and from 30 to 300 minutes perfusion represents the rapid initial transfer of cortisol and the steady flow of cortisol through the placenta respectively. Serotonin concentration in the fetal system after 60 minutes and from 60 to 300 minutes perfusion represents the size of the initial peak in serotonin concentration in the fetal system. The concentration values in fetal system are presented as percentage (%) of the added cortisol and serotonin in maternal system (M0 sample). Sum of 5-HIAA concentration in fetal and maternal systems at 6 hours perfusion, presented as % of serotonin in M0 sample.

(DOCX)

###### 

Click here for additional data file.

###### Correlations between maternal stress exposure and fetal exposure to tested hormones.

Bivariate correlations between: State stress represented by DASS, PRA, life events and adjusted fetal cortisol exposure (AFCE), trait stress represented by NEO-FFI categories neuroticism and conscientiousness. Cortisol concentration in the fetal system after 30 minutes and from 30 to 300 minutes perfusion represents the rapid initial transfer of cortisol and the steady flow of cortisol through the placenta respectively. Serotonin concentration in the fetal system after 60 minutes and from 60 to 300 minutes perfusion represents the size of the initial peak in serotonin concentration in the fetal system. The concentration values in fetal system are presented as % of the added cortisol and serotonin in maternal system (M0 sample). Sum of 5-HIAA concentration in fetal and maternal systems at 6 hours perfusion, presented as % of serotonin in M0 sample. Correlations were seen between stress variables: life-events, DASS depression, anxiety and stress, and FFI neuroticism. Reverse correlations were seen between related hormone exposure variables: fetal cortisol 30 minutes and Δ fetal cortisol 30--300 minutes, and fetal serotonin 60 minutes and Δ fetal serotonin 60--300 minutes.

(DOCX)

###### 

Click here for additional data file.

###### Raw data from perfusions with added cortisol, cortisone, tryptophan and serotonin.

Data are presented in nM for cortisol, cortisone, tryptophan, serotonin and the metabolite 5-HIAA for each time-point in the perfusions from maternal and fetal system (n = 22). Missing data are due to analysis errors.

(XLSX)

###### 

Click here for additional data file.

This project would never have succeeded without the invaluable assistance of Dr. Morten Hedegaard and the personnel at the maternity ward at Copenhagen University Hospital and all the participating pregnant women and their families. Sampling assistance was given by Julie Hansen Lawrence.

5-HIAA

:   5- hydroxyindoleacetic acid, a metabolite of serotonin

5-HT

:   5-hydroxytryptamine, also called serotonin

11β-HSD2

:   11β-Hydroxysteroid dehydrogenase, a placental enzyme that transforms cortisol into cortisone

BMI

:   body mass index

HSA

:   human serum albumin

DASS-42

:   a questionnaire measuring depression, anxiety and stress

IDO1 and 2

:   indoleamine 2,3-dioxygenase-1 and -2, an enzyme in the kynurenine pathway

MAO A

:   Monoamine oxidase A

NEO-FFI

:   NEO Five Factor Inventory, a measure of the personality traits of Neuroticism, Extraversion, Openness, Conscientiousness and Agreeableness

PRA

:   Pregnancy-Related Anxiety

SERT

:   Serotonin transporter

SSRI

:   Selective serotonin receptor inhibitor

TPH1 and 2

:   Tryptophan hydroxylase 1 and 2, an enzyme in the serotonin pathway

10.1371/journal.pone.0233979.r001
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Dear Mathiesen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses ALL the points raised during the review process.

We would appreciate receiving your revised manuscript by May 23 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the ***Financial Disclosure*** section:

\"GW reports to have received lecture/consultancy fees/research support from H. Lundbeck A/S, Servier SA, Astra Zeneca AB, Eli Lilly A/S, Sun Pharma Pty Ltd, Pfizer Inc, Shire A/S, HB Pharma A/S, Arla Foods A.m.b.A., Alkermes Inc, Mundipharma International Ltd., and Jannsen Pharmaceuticals A/S. No other conflicts of interests are reported.\"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank)).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

3\. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere.

\"Yes, the individual AFCE ratios and the Stress levels of the participating women are published as a part of a another paper as the participants in this paper are a subset of a previously studied population. The current studied subset is unidentifiable from the previous publication with is referenced in the text, and the study presented here is completely different. \"

Please clarify whether this \[conference proceeding or publication\] was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: An innovative and valuable way to test the validity of the results in placenta-fetal metabolism in laboratory animals has been devised and used to study long term consequences of the gestational milieu. In this case it tests the impact of human maternal stress on the key modulators of the HPA axis in the fetus.

Reviewer \#2: REVIEW PONE

Investigators collected term placentas from 22 women, and performed ex vivo perfusion concurrently (simultaneously) with cortisol, 5HT and tryptophan with and without inhibitors for treatments for 6 h successfully on 16 placentas. Cortisol was converted to cortisone by placenta, and was somewhat inhibited by carb, resulting in increased cortisol on fetal side. PCBA had no effect, whereas fluoxotine increased fetal side 5HT.

There is some merit in the manuscript, but the quality of writing is OK at best, and sloppy with an overuse abbreviations making it impossible to read fluidly and understand. I am not sure any of the maternal 'stress' information adds to the paper, as the sample size was too small to do analysis, and so mentioning it detracts from findings, etc., you may be better off indicating that placentas were collected as part of a larger study that was focused on understanding role of maternal stress on offspring development. There are no indicators of statistical significance of changes in hormone levels in response to treatments, that that because there are none? Please state within files.

line 17 which can cause changed health conditions, what is meant by this? I think you mean 'has potential long-term effects on offspring's development and health'

line 31 maternal \'stress\' the n was really too small to analyze this

line 36, edit seen to \'evident\'

needs to be define, 11BHSD2, line 59

line 67, as written suggests that 5HT is transported across placenta by SERT, whereas uptake of 5HT by SERT targets it for degradation via the pathway referred.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084180/> fetal 5HT source is not of maternal origin. Using additional genetic strategies, a new technology for studying placental biology ex vivo, and direct manipulation of placental neosynthesis, we investigated the nature of this exogenous source and uncovered a placental 5-HT synthetic pathway from a maternal tryptophan precursor, in both mice and humans.

although this paper suggests SERT SNP, may affect fetal exposure levels. <https://www.ncbi.nlm.nih.gov/pubmed/27550733>

ine 103, twenty-two

line 103-105, sentence needs editing for sense

line 127, define HAS

line 142, cortisole=cortisol

line 146, space between test

line 208 what was the number?

Line 226, define tendency, what was p-value, what was difference?

Line 232, the graphs show

line 241 at the end of

line 264 subtract 'from' the

line 340 write out TDo, over use of abbreviations

line 349, what is normal?

line 354, write out LOQ

As written the conclusion is confusing and not easy to follow

line 366, an hour after beginning perfusion of fluoxetine.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Elise P. Gomez-Sanchez

Reviewer \#2: Yes: Theresa M Casey

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewers\' comments:

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

Corrections are made as suggested by the reviewer

Reviewer \#1: An innovative and valuable way to test the validity of the results in placenta-fetal metabolism in laboratory animals has been devised and used to study long term consequences of the gestational milieu. In this case it tests the impact of human maternal stress on the key modulators of the HPA axis in the fetus.

We thank the reviewer for this comment, we also believe the data presented are valuable in its' field.

Reviewer \#2: REVIEW PONE

Investigators collected term placentas from 22 women, and performed ex vivo perfusion concurrently (simultaneously) with cortisol, 5HT and tryptophan with and without inhibitors for treatments for 6 h successfully on 16 placentas. Cortisol was converted to cortisone by placenta, and was somewhat inhibited by carb, resulting in increased cortisol on fetal side. PCBA had no effect, whereas fluoxotine increased fetal side 5HT.

There is some merit in the manuscript, but the quality of writing is OK at best, and sloppy with an overuse abbreviations making it impossible to read fluidly and understand.

We thank the reviewer for this comment, and have tried to improve the quality of writing and avoid the overuse of abbreviations.

I am not sure any of the maternal 'stress' information adds to the paper, as the sample size was too small to do analysis, and so mentioning it detracts from findings, etc., you may be better off indicating that placentas were collected as part of a larger study that was focused on understanding role of maternal stress on offspring development.

We thank the reviewer for this comment. We believe the presentation of the maternal stress --though not showing significant result, could demonstrate the methods used and inspire future researchers in this area, if only to show that future research needs to include a larger population sample or more variation in population stress levels.

There are no indicators of statistical significance of changes in hormone levels in response to treatments, that that because there are none? Please state within files.

The statistical significance of treatments is not tested due the few repetitions, only observations are made. This is now stated in the manuscript.

line 17 which can cause changed health conditions, what is meant by this? I think you mean 'has potential long-term effects on offspring's development and health'

The change is made as suggested.

line 31 maternal \'stress\' the n was really too small to analyze this

The statement "with no effect of adding PCPA" is deleted.

line 36, edit seen to \'evident\' needs to be define,

The change is made as suggested.

11BHSD2, line 59

The name of the enzyme is written in full at the first mention as suggested.

line 67, as written suggests that 5HT is transported across placenta by SERT, whereas uptake of 5HT by SERT

targets it for degradation via the pathway referred.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084180/> fetal 5HT source is not of maternal origin. Using additional genetic strategies, a new technology for studying placental biology ex vivo, and direct manipulation of placental neosynthesis, we investigated the nature of this exogenous source and uncovered a placental 5-HT synthetic pathway from a maternal tryptophan precursor, in both mice and humans.

although this paper suggests SERT SNP, may affect fetal exposure levels. <https://www.ncbi.nlm.nih.gov/pubmed/27550733>

Thank you for this comment. We realize that the literature differs in the origin of the fetal serotonin. This manuscript presents data that shows the possible effect of increased levels of maternal serotonin causing a transient increased level of serotonin on the fetal side of placenta, thus supporting some correlation between maternal and fetal serotonin levels. If this increase is caused by transport via the SERT remains to be established.

ine 103, twenty-two

The correction is made as suggested.

line 103-105, sentence needs editing for sense

The sentence is edited as follows: Of these, 2 perfusions had a leak of medium from fetal circulation and were unsuccessful, 5 perfusions showed a leak of medium from the fetal circulation after 4 hours perfusion and were thus unsuccessful after this time-point, and 15 were successful 6-hour perfusions.

line 127, define HAS

HSA is written out as human serum albumin.

line 142, cortisole=cortisol

The change is made as suggested.

line 146, space between test

The change is made as suggested.

line 208 what was the number?

The number is added (n=22).

Line 226, define tendency, what was p-value, what was difference?

The statement is an observation and does not include statistical measures, the term "tendency" is deleted.

Line 232, the graphs show

The change is made as suggested.

line 241 at the end of

The change is made as suggested.

line 264 subtract 'from' the

The change is made as suggested.

line 340 write out TDo, over use of abbreviations

The change is made as suggested.

line 349, what is normal?

The term normal means relatively unselected in this case, and is therefore deleted.

line 354, write out LOQ

The change is made as suggested.

As written the conclusion is confusing and not easy to follow

Thank you for this observation, the conclusion is rewritten in part to aid understanding:

Perfusions were performed on twenty-two placentas studying the effect of maternal stress levels and relevant enzymes on the placental transfer and metabolism on four chosen hormones: cortisol, cortisone, tryptophan and serotonin. The addition of carbenoxolone inhibitis the metabolism of cortisol in the placenta, and this increased the fetal levels of cortisol in our experiments as expected. Unexpectedly we saw a peak in fetal levels of serotonin an hour after beginning perfusion, in placental perfusions of serotonin with added fluoxetine that inhibits the serotonin transporter. This was observed together with a delayed decrease in serotonin concentration on maternal side which suggests that the increased fetal levels of serotonin is caused by increased serotonin concentration on the maternal side of the placenta, perhaps enabling other transplacental serotonin transport routes than through the SERT. The effect of maternal stress on placental transporters and enzymes, represented in this study by adding inhibitors, can thus affect the fetal exposure to maternal cortisol and serotonin levels. The more direct interpretation is increased transient exposure to both cortisol and serotonin when treating pregnant women with enzyme inhibitors. The increased fetal exposure to serotonin when inhibiting the SERT is an interesting finding, especially as regards to pregnant women needing treatment with SSRIs due to major depressive disorder and PTSD. No effect on placental kinetics was seen on maternal stress levels during the pregnancy, which is probably due to small group size in this study and the low to normal stress levels in the majority of most participating mothers.

line 366, an hour after beginning perfusion of fluoxetine.

The sentence is changed as follows: an hour after beginning perfusion, in placental perfusions of serotonin with added fluoxetine\...
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Dear Dr. Mathiesen,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The authors addressed my comments\--but I suggest a very thorough read theough and editing by a native English speaker, there are still problems here and PLoSOne does not copy edit.

For example line 202 \'are\' shuld be were\--as this was done in past/\....authors use \'are\' are\' are, and then switch tense. Again the writing is quite sloppy and not a good reflection of qulaity.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No
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Dear Dr. Mathiesen:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Frank T. Spradley

Academic Editor

PLOS ONE
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